#5 Clinical Trend: High Alkaline Phosphatase
Intercept Pharmaceuticals, Inc. announced submission of a new drug application to the US Food and Drug Administration (FDA). The company is seeking approval of obeticholic acid to treat primary biliary cirrhosis (PBC). Alkaline phosphatase (ALP) levels are elevated in patients with PBC, and this corresponds to an increased risk of liver failure among other serious concerns. This drug would attempt to correct for that elevation and could be an important tool.
For more in-depth clinical information, see Primary Billiary Cirrhosis.
Medscape © 2015
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Ryan Syrek. Top 10 Clinical Trends for July 2015 - Medscape - Jul 22, 2015.